Absence 0 7 0 7 O
of 8 10 8 10 O
documentation 11 24 11 24 O
in 25 27 25 27 O
the 28 31 28 31 O
medical 32 39 32 39 O
record 40 46 40 46 O
of 47 49 47 49 O
clinical 50 58 50 58 O
remission 59 68 59 68 O
for 69 72 69 72 O
the 73 76 73 76 O
last 77 81 77 81 B-upper_bound
6 82 83 82 83 I-upper_bound
months 84 90 84 90 I-upper_bound

Absence 0 7 91 98 O
of 8 10 99 101 O
documentation 11 24 102 115 O
of 25 27 116 118 O
age 28 31 119 122 B-age
- 31 32 122 123 O
appropriate 32 43 123 134 O
cancer 44 50 135 141 O
screening 51 60 142 151 O
at 61 63 152 154 O
the 64 67 155 158 O
time 68 72 159 163 O
of 73 75 164 166 O
randomization 76 89 167 180 O

Absence 0 7 181 188 O
of 8 10 189 191 O
documentation 11 24 192 205 O
of 25 27 206 208 O
negative 28 36 209 217 O
hepatitis 37 46 218 227 B-chronic_disease
B 47 48 228 229 I-chronic_disease
serologies 49 59 230 240 O
, 59 60 240 241 O
absence 61 68 242 249 O
of 69 71 250 252 O
completion 72 82 253 263 O
of 83 85 264 266 O
treatment 86 95 267 276 B-treatment
for 96 99 277 280 O
chronic 100 107 281 288 B-chronic_disease
hepatitis 108 117 289 298 I-chronic_disease
B 118 119 299 300 I-chronic_disease
, 119 120 300 301 O
or 121 123 302 304 O
absence 124 131 305 312 O
of 132 134 313 315 O
suppressive 135 146 316 327 B-treatment
antiviral 147 156 328 337 I-treatment
treatment 157 166 338 347 I-treatment

Absence 0 7 348 355 O
of 8 10 356 358 O
documentation 11 24 359 372 O
of 25 27 373 375 O
negative 28 36 376 384 O
tuberculin 37 47 385 395 B-treatment
skin 48 52 396 400 I-treatment
test 53 57 401 405 I-treatment
, 57 58 405 406 O
negative 59 67 407 415 O
QuantiFERON 68 79 416 427 B-treatment
- 79 80 427 428 I-treatment
TB 80 82 428 430 I-treatment
Gold 83 87 431 435 I-treatment
test 88 92 436 440 I-treatment
, 92 93 440 441 O
or 94 96 442 444 O
treatment 97 106 445 454 B-treatment
for 107 110 455 458 O
latent 111 117 459 465 B-chronic_disease
tuberculosis 118 130 466 478 I-chronic_disease
prior 131 136 479 484 O
to 137 139 485 487 O
starting 140 148 488 496 O
treatment 149 158 497 506 B-treatment
with 159 163 507 511 I-treatment
the 164 167 512 515 I-treatment
anti 168 172 516 520 I-treatment
- 172 173 520 521 I-treatment
TNF 173 176 521 524 I-treatment
agent 177 182 525 530 I-treatment

Age 0 3 531 534 B-age
greater 4 11 535 542 O
than 12 16 543 547 O
or 17 19 548 550 O
equal 20 25 551 556 O
to 26 28 557 559 O
18 29 31 560 562 B-lower_bound
years 32 37 563 568 I-lower_bound

Had 0 3 569 572 O
change 4 10 573 579 O
of 11 13 580 582 O
anti 14 18 583 587 B-treatment
- 18 19 587 588 I-treatment
TNF 19 22 588 591 I-treatment
agent 23 28 592 597 I-treatment
or 29 31 598 600 O
DMARD 32 37 601 606 B-treatment
in 38 40 607 609 O
the 41 44 610 613 O
last 45 49 614 618 B-upper_bound
6 50 51 619 620 I-upper_bound
months 52 58 621 627 I-upper_bound

Had 0 3 628 631 O
dose 4 8 632 636 O
increase 9 17 637 645 O
of 18 20 646 648 O
anti 21 25 649 653 B-treatment
- 25 26 653 654 I-treatment
TNF 26 29 654 657 I-treatment
agent 30 35 658 663 I-treatment
or 36 38 664 666 O
DMARD 39 44 667 672 B-treatment
in 45 47 673 675 O
the 48 51 676 679 O
last 52 56 680 684 B-upper_bound
6 57 58 685 686 I-upper_bound
months 59 65 687 693 I-upper_bound

In 0 2 694 696 O
sustained 3 12 697 706 O
clinical 13 21 707 715 O
remission 22 31 716 725 O
for 32 35 726 729 O
the 36 39 730 733 O
last 40 44 734 738 B-upper_bound
6 45 46 739 740 I-upper_bound
months 47 53 741 747 I-upper_bound
while 54 59 748 753 O
receiving 60 69 754 763 O
treatment 70 79 764 773 B-treatment
with 80 84 774 778 O
either 85 91 779 785 O
etanercept 92 102 786 796 B-treatment
, 102 103 796 797 O
infliximab 104 114 798 808 B-treatment
, 114 115 808 809 O
or 116 118 810 812 O
adalimumab 119 129 813 823 B-treatment
, 129 130 823 824 O
and 131 134 825 828 O
greater 135 142 829 836 O
than 143 147 837 841 O
or 148 150 842 844 O
equal 151 156 845 850 O
to 157 159 851 853 O
1 160 161 854 855 B-lower_bound
DMARD 162 167 856 861 O
( 168 169 862 863 O
methotrexate 169 181 863 875 B-treatment
, 181 182 875 876 O
hydroxychloroquine 183 201 877 895 B-treatment
, 201 202 895 896 O
sulfasalazine 203 216 897 910 B-treatment
, 216 217 910 911 O
leflunomide 218 229 912 923 B-treatment
, 229 230 923 924 O
minocycline 231 242 925 936 B-treatment
, 242 243 936 937 O
cyclosporine 244 256 938 950 B-treatment
, 256 257 950 951 O
azathioprine 258 270 952 964 B-treatment
, 270 271 964 965 O
gold 272 276 966 970 O
, 276 277 970 971 O
penicillamine 278 291 972 985 B-treatment
) 291 292 985 986 O
. 292 293 986 987 O
DAS28 294 299 988 993 B-clinical_variable
should 300 306 994 1000 O
be 307 309 1001 1003 O
less 310 314 1004 1008 O
than 315 319 1009 1013 O
2.6 320 323 1014 1017 B-upper_bound
on 324 326 1018 1020 O
each 327 331 1021 1025 O
visit 332 337 1026 1031 O
over 338 342 1032 1036 O
the 343 346 1037 1040 O
preceding 347 356 1041 1050 O
6 357 358 1051 1052 O
months 359 365 1053 1059 O
, 365 366 1059 1060 O
with 367 371 1061 1065 O
at 372 374 1066 1068 O
least 375 380 1069 1074 O
one 381 384 1075 1078 B-lower_bound
visit 385 390 1079 1084 O
2 391 392 1085 1086 O
- 392 393 1086 1087 O
4 393 394 1087 1088 B-upper_bound
months 395 401 1089 1095 I-upper_bound
before 402 408 1096 1102 O
enrollment 409 419 1103 1113 O
. 419 420 1113 1114 O
If 421 423 1115 1117 O
there 424 429 1118 1123 O
is 430 432 1124 1126 O
no 433 435 1127 1129 O
visit 436 441 1130 1135 O
6 442 443 1136 1137 B-upper_bound
months 444 450 1138 1144 I-upper_bound
before 451 457 1145 1151 I-upper_bound
enrollment 458 468 1152 1162 O
, 468 469 1162 1163 O
the 470 473 1164 1167 O
nearest 474 481 1168 1175 O
visit 482 487 1176 1181 O
in 488 490 1182 1184 O
the 491 494 1185 1188 O
6 495 496 1189 1190 O
- 496 497 1190 1191 O
12 497 499 1191 1193 B-upper_bound
month 500 505 1194 1199 I-upper_bound
period 506 512 1200 1206 O
before 513 519 1207 1213 O
enrollment 520 530 1214 1224 O
should 531 537 1225 1231 O
be 538 540 1232 1234 O
considered 541 551 1235 1245 O
and 552 555 1246 1249 O
have 556 560 1250 1254 O
a 561 562 1255 1256 O
DAS28 563 568 1257 1262 O
less 569 573 1263 1267 O
than 574 578 1268 1272 O
2.6 579 582 1273 1276 O

Pregnant 0 8 1277 1285 B-pregnancy
( 9 10 1286 1287 O
or 10 12 1287 1289 O
anticipate 13 23 1290 1300 B-pregnancy
pregnancy 24 33 1301 1310 I-pregnancy
during 34 40 1311 1317 O
the 41 44 1318 1321 O
study 45 50 1322 1327 O
period 51 57 1328 1334 O
) 57 58 1334 1335 O

Treated 0 7 1336 1343 O
currently 8 17 1344 1353 O
with 18 22 1354 1358 O
golimumab 23 32 1359 1368 B-treatment
or 33 35 1369 1371 O
certolizumab 36 48 1372 1384 B-treatment

Treated 0 7 1385 1392 O
with 8 12 1393 1397 O
an 13 15 1398 1400 O
investigational 16 31 1401 1416 B-treatment
RA 32 34 1417 1419 I-treatment
drug 35 39 1420 1424 I-treatment
in 40 42 1425 1427 O
the 43 46 1428 1431 O
last 47 51 1432 1436 B-upper_bound
6 52 53 1437 1438 I-upper_bound
months 54 60 1439 1445 I-upper_bound

Treated 0 7 1446 1453 O
with 8 12 1454 1458 O
anakinra 13 21 1459 1467 B-treatment
, 21 22 1467 1468 O
abatacept 23 32 1469 1478 B-treatment
, 32 33 1478 1479 O
or 34 36 1480 1482 O
tocilizumab 37 48 1483 1494 B-treatment
in 49 51 1495 1497 O
the 52 55 1498 1501 O
last 56 60 1502 1506 B-upper_bound
6 61 62 1507 1508 I-upper_bound
months 63 69 1509 1515 I-upper_bound

Treated 0 7 1516 1523 O
with 8 12 1524 1528 O
greater 13 20 1529 1536 O
than 21 25 1537 1541 O
10 26 28 1542 1544 B-lower_bound
mg 29 31 1545 1547 I-lower_bound
of 32 34 1548 1550 O
prednisone 35 45 1551 1561 B-treatment
( 46 47 1562 1563 O
or 47 49 1563 1565 O
equivalent 50 60 1566 1576 O
) 60 61 1576 1577 O
daily 62 67 1578 1583 O
in 68 70 1584 1586 O
the 71 74 1587 1590 O
last 75 79 1591 1595 B-upper_bound
6 80 81 1596 1597 I-upper_bound
months 82 88 1598 1604 I-upper_bound

Treated 0 7 1605 1612 O
with 8 12 1613 1617 O
greater 13 20 1618 1625 O
than 21 25 1626 1630 O
5 26 27 1631 1632 B-lower_bound
mg 28 30 1633 1635 I-lower_bound
of 31 33 1636 1638 O
prednisone 34 44 1639 1649 B-treatment
( 45 46 1650 1651 O
or 46 48 1651 1653 O
equivalent 49 59 1654 1664 O
) 59 60 1664 1665 O
daily 61 66 1666 1671 O
in 67 69 1672 1674 O
the 70 73 1675 1678 O
last 74 78 1679 1683 B-upper_bound
3 79 80 1684 1685 I-upper_bound
months 81 87 1686 1692 I-upper_bound

Treated 0 7 1693 1700 O
with 8 12 1701 1705 O
intramuscular 13 26 1706 1719 O
or 27 29 1720 1722 O
intravenous 30 41 1723 1734 O
corticosteroids 42 57 1735 1750 B-treatment
in 58 60 1751 1753 O
the 61 64 1754 1757 O
last 65 69 1758 1762 B-upper_bound
6 70 71 1763 1764 I-upper_bound
months 72 78 1765 1771 I-upper_bound
for 79 82 1772 1775 O
RA 83 85 1776 1778 O
activity 86 94 1779 1787 O

Treated 0 7 1788 1795 B-treatment
with 8 12 1796 1800 I-treatment
rituximab 13 22 1801 1810 I-treatment
in 23 25 1811 1813 O
the 26 29 1814 1817 O
last 30 34 1818 1822 B-upper_bound
12 35 37 1823 1825 I-upper_bound
months 38 44 1826 1832 I-upper_bound

Treatment 0 9 1833 1842 B-treatment
of 10 12 1843 1845 O
solid 13 18 1846 1851 B-cancer
malignancy 19 29 1852 1862 I-cancer
or 30 32 1863 1865 O
non 33 36 1866 1869 B-cancer
- 36 37 1869 1870 I-cancer
melanoma 37 45 1870 1878 I-cancer
skin 46 50 1879 1883 I-cancer
cancer 51 57 1884 1890 I-cancer
within 58 64 1891 1897 O
the 65 68 1898 1901 O
past 69 73 1902 1906 B-upper_bound
5 74 75 1907 1908 I-upper_bound
years 76 81 1909 1914 I-upper_bound

Unwilling 0 9 1915 1924 O
to 10 12 1925 1927 O
discontinue 13 24 1928 1939 O
anti 25 29 1940 1944 B-treatment
- 29 30 1944 1945 I-treatment
TNF 30 33 1945 1948 I-treatment
agent 34 39 1949 1954 I-treatment

any 0 3 1955 1958 O
history 4 11 1959 1966 O
of 12 14 1967 1969 O
melanoma 15 23 1970 1978 B-cancer
or 24 26 1979 1981 O
hematologic 27 38 1982 1993 B-cancer
or 39 41 1994 1996 O
lymphoproliferative 42 61 1997 2016 B-cancer
malignancy 62 72 2017 2027 I-cancer

lactating 0 9 2028 2037 O
women 10 15 2038 2043 B-gender

